by emma
21. September 2011 15:04
Sanofi Pasteur has signed a research and development agreement with the University of California, San Diego, for its experimental acne vaccine and treatment.
The R&D pact includes a two-year collaboration with Chun-Ming Huang and team at UC San Diego School of Medicine.
The team’s immunological approach to acne prevention and treatment targets the neutralisation of Propionibacterium inflammation.
Elias Zerhouni, President of Global Research and Development at Sanofi, said that the vaccine and treatment could address an unmet medical need.
“This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease,” said Mr Zerhouni.
According to the vaccine division of Sanofi, the annual market for acne therapeutics is in excess of $3 billion.
8307375b-38af-4e36-aa81-8b55c2b7c0ea|0|.0
Tags: Sanofi, Sanofi Pasteur, R&D, research, development, research and development, agreement, deal, pact, collaboration, collaborate, acne, vaccine, vaccinate, vaccination, vaccinations, experimental, treatment, therapy, cure, Chun Ming Huang, Chun-Ming Huang, UC San Diego, School of Medicine, medicine, medication, medicines, medications, drug, drugs, pharma, pharmaceutical, pharmaceuticals, pharmafield, pharma field, pharmaceutical field, pharmaceuticalfield, pf, product news, pharma news uk, immunological, immunology, prevention, neutralise, neutral, neutralisation, propionibacterium, inflammation, inflame, inflamed, Elias Zerhouni, President, Global, medical, medical sale, medical sales, market, therapeutics
News
Subscribe